Gastrointestinal Cancer Program The Gastrointestinal (GI) Cancer Program is a team of clinician scientists and translational investigators who work collaboratively towards the goal of reducing the morbidity and mortality of GI cancers. GI cancers account for a substantial portion of cancer related deaths in the US and, in aggregate, are the most common cancer in the US. The most common GI cancers are colorectal cancer (143,000 cases/year), upper GI cancers (17,000 esophageal cancers and 21,000 stomach cancers/year), liver cancer (29,000 cases/year), and pancreatic cancer (44,000 cases/year). Thus, the GI Cancer Program has emphasized esophageal adenocarcinoma, pancreatic cancer, liver cancer, and colorectal cancer. The program has formed multidisciplinary care teams and integrative research teams to provide cutting-edge clinical care that incorporates innovative therapeutic trials into the care plans. Examples of these innovations include stromal directed therapy for pancreatic cancer and state of the art molecular diagnostic assay development. There are 32 members in the program, from two institutions, three schools and 14 different divisions and departments. Research themes of the GI cancer program are focused on: 1) investigation of the molecular features that drive the initiation and progression of upper and lower GI cancers; 2) investigation of the host and tumor factors that govern the behavior of GI cancers; 3) development of novel therapies based on new insights into the behavior of cancers; and 4) development of novel molecular diagnostics for the early detection and treatment of GI cancers. The studies are supported by $3.7M in peer-reviewed funding (direct) of which $2.5M is from the NCI (funding in 2013). Investigators in the GI Cancer Program have published 470 manuscripts, which included 12% intra-programmatic, 44% inter-programmatic, and 17% inter-institutional publications. The high percentage of inter-programmatic publications reflects the broad collaborations of the GI Cancer Program members.
The specific aims of the Gastrointestinal Cancer Program are to: 1) Develop novel biomarker assays that can be used for the prevention and/or early detection of colorectal, esophageal, and pancreatic cancers and for risk-stratification for these cancers and liver cancer. 2) Develop novel therapeutic strategies for the treatment of pancreatic cancers directed at the tumor microenvironment. 3) Determine the molecular alterations in the major GI cancers (esophagus, stomach, pancreas, liver, and colon) and use the molecular profiles to inform and effectively treat the cancers.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Career Development (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Hempstead, Bridgette; Green, Cynthia; Briant, Katherine J et al. (2018) Community Empowerment Partners (CEPs): A Breast Health Education Program for African-American Women. J Community Health 43:833-841
OhAinle, Molly; Helms, Louisa; Vermeire, Jolien et al. (2018) A virus-packageable CRISPR screen identifies host factors mediating interferon inhibition of HIV. Elife 7:
Syrjala, Karen L; Yi, Jean C; Artherholt, Samantha B et al. (2018) An online randomized controlled trial, with or without problem-solving treatment, for long-term cancer survivors after hematopoietic cell transplantation. J Cancer Surviv 12:560-570
Liu, Yang; He, Qianchan; Sun, Wei (2018) Association analysis using somatic mutations. PLoS Genet 14:e1007746
Glaser, Adam K; Chen, Ye; Yin, Chengbo et al. (2018) Multidirectional digital scanned light-sheet microscopy enables uniform fluorescence excitation and contrast-enhanced imaging. Sci Rep 8:13878
Liu, Yanyan; Xiong, Sican; Sun, Wei et al. (2018) Joint Analysis of Strain and Parent-of-Origin Effects for Recombinant Inbred Intercrosses Generated from Multiparent Populations with the Collaborative Cross as an Example. G3 (Bethesda) 8:599-605
Mora-Pinzon, Maria C; Trentham-Dietz, Amy; Gangnon, Ronald E et al. (2018) Urinary Magnesium and Other Elements in Relation to Mammographic Breast Density, a Measure of Breast Cancer Risk. Nutr Cancer 70:441-446
Shirts, Brian H; Konnick, Eric Q; Upham, Sarah et al. (2018) Using Somatic Mutations from Tumors to Classify Variants in Mismatch Repair Genes. Am J Hum Genet 103:19-29
Du, Jing; Flynn, Ryan; Paz, Katelyn et al. (2018) Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients. Blood 131:1743-1754
Suzuki, Aussie; Gupta, Amitabha; Long, Sarah K et al. (2018) A Kinesin-5, Cin8, Recruits Protein Phosphatase 1 to Kinetochores and Regulates Chromosome Segregation. Curr Biol 28:2697-2704.e3

Showing the most recent 10 out of 1267 publications